Jim Simons
ABEO icon

Jim Simons’s Abeona Therapeutics ABEO Stock Holding History

Jim Simons’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$722K Buy
161,082
+44,882
+39% +$224K ﹤0.01% 2431
2025
Q4 		$612K Sell
116,200
-410,237
-78% -$2.07M ﹤0.01% 2496
2025
Q3 		$2.78M Buy
526,437
+226,500
+76% +$1.44M ﹤0.01% 1858
2025
Q2 		$1.7M Buy
299,937
+168,400
+128% +$959K ﹤0.01% 2215
2025
Q1 		$626K Buy
131,537
+42,300
+47% +$230K ﹤0.01% 2647
2024
Q4 		$497K Sell
89,237
-45,041
-34% -$277K ﹤0.01% 2846
2024
Q3 		$849K Sell
134,278
-369,015
-73% -$1.93M ﹤0.01% 2547
2024
Q2 		$2.13M Buy
503,293
+429,456
+582% +$2.19M ﹤0.01% 1846
2024
Q1 		$535K Sell
73,837
-108,556
-60% -$688K ﹤0.01% 2833
2023
Q4 		$914K Buy
182,393
+151,556
+491% +$667K ﹤0.01% 2465
2023
Q3 		$130K Sell
30,837
-2,700
-8% -$10.2K ﹤0.01% 3193
2023
Q2 		$135K Sell
33,537
-3,300
-9% -$11.5K ﹤0.01% 3397
2023
Q1 		$104K Sell
36,837
-25,800
-41% -$67.4K ﹤0.01% 3483
2022
Q4 		$193K Sell
62,637
-5,500
-8% -$20.6K ﹤0.01% 3434
2022
Q3 		$207K Sell
68,137
-27,790
-29% -$115K ﹤0.01% 3369
2022
Q2 		$499K Buy
95,927
+2,894
+3% +$14.6K ﹤0.01% 3165
2022
Q1 		$733K Buy
93,033
+5,928
+7% +$40.7K ﹤0.01% 2931
2021
Q4 		$734K Buy
87,105
+85,125
+4,299% +$1.56M ﹤0.01% 2879
2021
Q3 		$55K Buy
+1,980
New +$63.4K ﹤0.01% 3368
2021
Q2 		– Sell
-20,891
Closed -$982K – 3408
2021
Q1 		$982K Sell
20,891
-32,025
-61% -$1.76M ﹤0.01% 2617
2020
Q4 		$2.08M Buy
52,916
+45,706
+634% +$1.56M ﹤0.01% 2094
2020
Q3 		$184K Sell
7,210
-131
-2% -$8.26K ﹤0.01% 3127
2020
Q2 		$535K Buy
7,341
+4,332
+144% +$299K ﹤0.01% 2851
2020
Q1 		$158K Buy
+3,009
New +$201K ﹤0.01% 3142

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jim Simons's ABEO Position: Q1 2026 in Review

Jim Simons increased its Abeona Therapeutics (ABEO) stake by 39% in Q1 2026, buying an estimated $224K and bringing the position to 161,082 shares worth $722K. The position accounts for ﹤0.01% of the portfolio, ranked #2431.

Jim Simons first reported a position in ABEO in Q1 2020 and has held it in 24 quarters since. The position peaked at $2.78M in Q3 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Jim Simons held 161,082 shares of Abeona Therapeutics worth $722K as of Q1 2026.
  • Jim Simons bought 44,882 Abeona Therapeutics shares in Q1 2026, an estimated $224K.
  • Abeona Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2431 holding.
  • Jim Simons first reported a position in Abeona Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • Jim Simons's Abeona Therapeutics position peaked at $2.78M in Q3 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.